<DOC>
	<DOC>NCT01031277</DOC>
	<brief_summary>The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations: - Primary/secondary prevention patients. - Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations: - Primary/secondary prevention patients. - Patients with metabolic syndrome.</brief_summary>
	<brief_title>Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Race On lipidlowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. Subject must sign informed consent Subjects who are unwilling or unable to provide informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Update NCEP ATP111</keyword>
	<keyword>Survey</keyword>
</DOC>